A case of a woman with Schönlein-Henoch glomerulonephritis and liver cirrhosis and a monoclonal peak in the proteinogram is reported. An attempt is made to differentiate the benign monoclonal gammapathy from Waldenström's disease according to the existing criteria. The conclusion is reached that at present there is no index or a combination of indices which could allow a definite assessment. Only the prolonged systematic observation with repeated examinations could allow a more precise assessment of the pathologic process.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Lupus nephritis: Biomarkers.
Adv Clin Chem
January 2025
University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, ON, Canada. Electronic address:
Lupus nephritis (LN) or renal involvement of systemic lupus erythematosus (SLE), is a common manifestation occurring in at least 50 % of SLE patients. LN remains a significant source of morbidity, often leading to progressive renal dysfunction and is a major cause of death in SLE. Despite these challenges, advances in the understanding of the pathogenesis and genetic underpinnings of LN have led to a commendable expansion in available treatments over the past decade.
View Article and Find Full Text PDFgene polymorphisms are associated with cyclophosphamide effectiveness in lupus nephritis patients: A case-control study in Indonesia.
Narra J
December 2024
Department of Pharmacology-Clinical Pharmacy, School of Pharmacy, Institut Teknologi Bandung, Bandung, Indonesia.
Glutathione-S-transferase alpha-1 () is an enzyme with high conjugation activity against aldophosphamide, a metabolite of cyclophosphamide and promoter polymorphisms in may influence the cyclophosphamide effectiveness. The aim of this study was to evaluate the effectiveness and side effects of cyclophosphamide in lupus nephritis patients, using variants as predictors. A case-control study was conducted at Hasan Sadikin Hospital, Bandung, Indonesia, involving 100 lupus nephritis patients from February 2023 to January 2024.
View Article and Find Full Text PDF[Nephrology: what's new in 2024 (I)].
Rev Med Suisse
January 2025
Service de néphrologie et d'hypertension, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.
From immunoglobulin A nephropathy to primary focal segmental glomerulosclerosis, sparsentan expands its indications. Complement inhibitors offer new hope for patients with certain poor-prognosis glomerulonephritides. Semaglutide enjoys great success, promising nephro- and cardioprotection for type 2 diabetics.
View Article and Find Full Text PDFEffectiveness of a Novel PLA2R1 Knock-In Rat Model in Repairing Renal Function Damage.
J Biochem Mol Toxicol
January 2025
Shanxi Genetic Engineering Center for Experimental Animal Models, The Fifth Hospital (Shanxi Provincial People's Hospital) of Shanxi Medical University, Taiyuan, Shanxi, China.
Phospholipase A2 receptor 1 (PLA2R1) exists in many animals and plays an important role in membranous nephropathy. In this study, we aimed to evaluate a PLA2R1 knock-in rat model with repaired kidney function to study the molecular mechanisms of membranous nephropathy. We constructed the PLA2R1 knockout [PLA2R1(-)] model and PLA2R1 knock in [PLA2R1(+)] model in rats.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!